SCHEMBL6856291

SCHEMBL6856291

COc1ccc(C=CC(=O)NCCc2ccc3c(c2)OCO3)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.70
▸ MAPT P10636 9/20 0.68
▸ LMNA P02545 4/20 0.66
▸ TP53 P04637 1/20 0.65
▸ HDAC1 Q13547 2/20 0.62
▸ HDAC6 Q9UBN7 2/20 0.62
▸ HDAC3 O15379 1/20 0.62
▸ HDAC4 P56524 1/20 0.62
▸ HDAC7 Q8WUI4 1/20 0.62
▸ HDAC2 Q92769 1/20 0.62
▸ HDAC10 Q969S8 1/20 0.62
▸ HDAC11 Q96DB2 1/20 0.62
▸ HDAC8 Q9BY41 1/20 0.62
▸ HDAC9 Q9UKV0 1/20 0.62
▸ HDAC5 Q9UQL6 1/20 0.62
▸ ALDH1A1 P00352 6/20 0.62
▸ MEN1 O00255 3/20 0.62
▸ KMT2A Q03164 3/20 0.62
▸ KDM4E B2RXH2 3/20 0.62
▸ RAB9A P51151 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1617706 0.94 KDM4E (0.68) HPGDMAPTLMNAHDAC1HDAC6
SCHEMBL5374706 0.94 KDM4E (0.68) HPGDMAPTLMNAHDAC1HDAC6
SCHEMBL6859665 0.92 HPGD (0.73) HPGDMAPTLMNATP53HDAC1
SCHEMBL6647151 0.89 HPGD (0.89) HPGDMAPTLMNATP53HDAC1
SCHEMBL4881421 0.88 LMNA (0.71) HPGDMAPTLMNATP53HDAC1
SCHEMBL108118 0.88 LMNA (0.71) HPGDMAPTLMNATP53HDAC1
SCHEMBL14148886 0.88 L3MBTL1 (0.70) HPGDMAPTLMNATP53HDAC1
SCHEMBL29356447 0.88 L3MBTL1 (0.70) HPGDMAPTLMNATP53HDAC1
SCHEMBL6856497 0.88 L3MBTL1 (0.70) HPGDMAPTLMNATP53HDAC1
Zanthomamide SCHEMBL29407211 0.85 MAPT (0.87) HPGDMAPTLMNATP53HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831080-B2 E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents BRISTOL-MYERS SQUIBB COMPANY 2004-12-14 — — US disclosed
Send feedback